{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:44:25Z","timestamp":1794368665726,"version":"4.9.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The role of intestinal bacterial microbiota has been described as key in the pathophysiology of Crohn\u2019s disease (CD). CD is characterized by frequent relapses after periods of remission which are not entirely understood. In this paper, we investigate whether the heterogeneity in microbiota profiles in CD patients could be a suitable predictor for these relapses. This prospective observational study involved 259 CD patients, in which 41 provided an additional total of 62 consecutive fecal samples, with an average interval of 25\u00a0weeks in between each of these samples. Fecal microbiota was analyzed by massive genomic sequencing through 16 S rRNA amplicon sampling. We found that our 259 CD patients could be split into three distinct subgroups of microbiota (G1, G2, G3). From G1 to G3, we noticed a progressive decrease in alpha diversity (p\u2009\u2264\u20090.0001) but no change in the fecal calprotectin (FC) level. Focusing on the 103 consecutive samples from 41 CD patients, we showed that the patients microbiota profiles were remarkably stable over time and associated with increasing symptom severity. Investigating further this microbiota\/severity association revealed that the first signs of aggravation are (1) a loss of the main anti-inflammatory Short-Chain Fatty Acids (SCFAs) <jats:italic>Roseburia, Eubacterium<\/jats:italic>, <jats:italic>Subdoligranumum<\/jats:italic>, <jats:italic>Ruminococcus<\/jats:italic> (P\u2009&lt;\u20090.05), (2) an increase in pro-inflammatory pathogens <jats:italic>Proteus<\/jats:italic>, <jats:italic>Finegoldia<\/jats:italic> (P\u2009&lt;\u20090.05) while (3) an increase of other minor SCFA producers such as <jats:italic>Ezakiella<\/jats:italic>, <jats:italic>Anaerococcus<\/jats:italic><jats:italic>, <\/jats:italic><jats:italic>Megasphaera<\/jats:italic><jats:italic>, <\/jats:italic><jats:italic>Anaeroglobus<\/jats:italic>, <jats:italic>Fenollaria<\/jats:italic> (P\u2009&lt;\u20090.05). Further aggravation of clinical signs is significantly linked to the subsequent loss of these minor SCFAs species and to an increase in other proinflammatory Proteobacteria such as <jats:italic>Klebsiella, Pseudomonas, Salmonella, Acinetobacter, Hafnia<\/jats:italic> and proinflammatory Firmicutes such as <jats:italic>Staphylococcus, Enterococcus, Streptococcus.<\/jats:italic> (P\u2009&lt;\u20090.05). To our knowledge, this is the first study (1) specifically identifying subgroups of microbiota profiles in CD patients, (2) relating these groups to the evolution of symptoms over time and (3) showing a two-step process in CD symptoms\u2019 worsening. This paves the way towards a better understanding of patient-to-patient heterogeneity, as well as providing early warning signals of future aggravation of the symptoms and eventually adapting empirically treatments.<\/jats:p>","DOI":"10.1038\/s41598-022-23757-x","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T11:02:27Z","timestamp":1668855747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Gut microbiota analysis for prediction of clinical relapse in Crohn\u2019s disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Sylvie","family":"Buffet-Bataillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bouguen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Fleury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Cattoir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Le Cunff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,19]]},"reference":[{"key":"23757_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/ibd\/izy328","volume":"25","author":"N Dovrolis","year":"2019","unstructured":"Dovrolis, N. et al. Gut microbial signatures underline complicated Crohn\u2019s disease but vary between cohorts; an in silico approach. Inflamm. Bowel Dis. 25, 217\u2013225 (2019).","journal-title":"Inflamm. Bowel Dis."},{"key":"23757_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ijmm.2014.02.009","volume":"304","author":"M Lopez-Siles","year":"2014","unstructured":"Lopez-Siles, M. et al. Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish irritable bowel syndrome and inflammatory bowel disease phenotypes. Int. J. Med. Microbiol. IJMM 304, 464\u2013475 (2014).","journal-title":"Int. J. Med. Microbiol. IJMM"},{"key":"23757_CR3","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.3389\/fmicb.2018.02247","volume":"9","author":"T Zuo","year":"2018","unstructured":"Zuo, T. & Ng, S. C. The gut microbiota in the pathogenesis and therapeutics of inflammatory bowel disease. Front. Microbiol. 9, 2247 (2018).","journal-title":"Front. Microbiol."},{"key":"23757_CR4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41586-019-1237-9","volume":"569","author":"J Lloyd-Price","year":"2019","unstructured":"Lloyd-Price, J. et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature 569, 655\u2013662 (2019).","journal-title":"Nature"},{"key":"23757_CR5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.crohns.2012.07.012","volume":"7","author":"A Moradkhani","year":"2013","unstructured":"Moradkhani, A., Beckman, L. J. & Tabibian, J. H. Health-related quality of life in inflammatory bowel disease: Psychosocial, clinical, socioeconomic, and demographic predictors. J. Crohns Colitis 7, 467\u2013473 (2013).","journal-title":"J. Crohns Colitis"},{"key":"23757_CR6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/apt.13475","volume":"43","author":"SC Shah","year":"2016","unstructured":"Shah, S. C., Colombel, J.-F., Sands, B. E. & Narula, N. Systematic review with meta-analysis: Mucosal healing is associated with improved long-term outcomes in Crohn\u2019s disease. Aliment. Pharmacol. Ther. 43, 317\u2013333 (2016).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"23757_CR7","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","volume":"389","author":"J Torres","year":"2017","unstructured":"Torres, J., Mehandru, S., Colombel, J.-F. & Peyrin-Biroulet, L. Crohn\u2019s disease. Lancet Lond. Engl. 389, 1741\u20131755 (2017).","journal-title":"Lancet Lond. Engl."},{"key":"23757_CR8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2010.06.070","volume":"139","author":"KT Thia","year":"2010","unstructured":"Thia, K. T., Sandborn, W. J., Harmsen, W. S., Zinsmeister, A. R. & Loftus, E. V. Risk factors associated with progression to intestinal complications of Crohn\u2019s disease in a population-based cohort. Gastroenterology 139, 1147\u20131155 (2010).","journal-title":"Gastroenterology"},{"key":"23757_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/ecco-jcc\/jjv240","volume":"10","author":"G Fiorino","year":"2016","unstructured":"Fiorino, G., Bonifacio, C., Peyrin-Biroulet, L. & Danese, S. Preventing collateral damage in Crohn\u2019s disease: The L\u00e9mann index. J. Crohns Colitis 10, 495\u2013500 (2016).","journal-title":"J. Crohns Colitis"},{"key":"23757_CR10","first-page":"357","volume":"8","author":"S Vermeire","year":"2010","unstructured":"Vermeire, S., Schreiber, S., Sandborn, W. J., Dubois, C. & Rutgeerts, P. Correlation between the Crohn\u2019s disease activity and Harvey-Bradshaw indices in assessing Crohn\u2019s disease severity. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 8, 357\u2013363 (2010).","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"23757_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks808","volume":"41","author":"A Klindworth","year":"2013","unstructured":"Klindworth, A. et al. Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies. Nucleic Acids Res. 41, e1 (2013).","journal-title":"Nucleic Acids Res."},{"key":"23757_CR12","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/bioinformatics\/btx791","volume":"34","author":"F Escudi\u00e9","year":"2018","unstructured":"Escudi\u00e9, F. et al. FROGS: Find, rapidly, OTUs with galaxy solution. Bioinform. Oxf. Engl. 34, 1287\u20131294 (2018).","journal-title":"Bioinform. Oxf. Engl."},{"key":"23757_CR13","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.annepidem.2016.03.002","volume":"26","author":"MCB Tsilimigras","year":"2016","unstructured":"Tsilimigras, M. C. B. & Fodor, A. A. Compositional data analysis of the microbiome: Fundamentals, tools, and challenges. Ann. Epidemiol. 26, 330\u2013335 (2016).","journal-title":"Ann. Epidemiol."},{"key":"23757_CR14","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1038\/s41598-017-02606-2","volume":"7","author":"E Mossotto","year":"2017","unstructured":"Mossotto, E. et al. Classification of paediatric inflammatory bowel disease using machine learning. Sci. Rep. 7, 2427 (2017).","journal-title":"Sci. Rep."},{"key":"23757_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","volume":"17","author":"P Virtanen","year":"2020","unstructured":"Virtanen, P. et al. SciPy 1.0: Fundamental algorithms for scientific computing in Python. Nat. Methods 17, 261\u2013272 (2020).","journal-title":"Nat. Methods"},{"key":"23757_CR16","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng, S. C. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet Lond. Engl. 390, 2769\u20132778 (2017).","journal-title":"Lancet Lond. Engl."},{"key":"23757_CR17","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.gastro.2019.04.016","volume":"157","author":"D Piovani","year":"2019","unstructured":"Piovani, D. et al. Environmental risk factors for inflammatory bowel diseases: An umbrella review of meta-analyses. Gastroenterology 157, 647-659.e4 (2019).","journal-title":"Gastroenterology"},{"key":"23757_CR18","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/ajg.2012.335","volume":"107","author":"R Hansen","year":"2012","unstructured":"Hansen, R. et al. Microbiota of de-novo pediatric IBD: Increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn\u2019s but not in ulcerative colitis. Am. J. Gastroenterol. 107, 1913\u20131922 (2012).","journal-title":"Am. J. Gastroenterol."},{"key":"23757_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1136\/gut.2005.073817","volume":"55","author":"C Manichanh","year":"2006","unstructured":"Manichanh, C. et al. Reduced diversity of faecal microbiota in Crohn\u2019s disease revealed by a metagenomic approach. Gut 55, 205\u2013211 (2006).","journal-title":"Gut"},{"key":"23757_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/ibd.21436","volume":"17","author":"S Mondot","year":"2011","unstructured":"Mondot, S. et al. Highlighting new phylogenetic specificities of Crohn\u2019s disease microbiota. Inflamm. Bowel Dis. 17, 185\u2013192 (2011).","journal-title":"Inflamm. Bowel Dis."},{"key":"23757_CR21","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1136\/gutjnl-2015-310746","volume":"66","author":"H Sokol","year":"2017","unstructured":"Sokol, H. et al. Fungal microbiota dysbiosis in IBD. Gut 66, 1039\u20131048 (2017).","journal-title":"Gut"},{"key":"23757_CR22","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1136\/gutjnl-2016-313235","volume":"66","author":"V Pascal","year":"2017","unstructured":"Pascal, V. et al. A microbial signature for Crohn\u2019s disease. Gut 66, 813\u2013822 (2017).","journal-title":"Gut"},{"key":"23757_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s40168-018-0603-4","volume":"6","author":"JD Forbes","year":"2018","unstructured":"Forbes, J. D. et al. A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?. Microbiome 6, 221 (2018).","journal-title":"Microbiome"},{"key":"23757_CR24","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","volume":"371","author":"G D\u2019Haens","year":"2008","unstructured":"D\u2019Haens, G. et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn\u2019s disease: An open randomised trial. Lancet Lond. Engl. 371, 660\u2013667 (2008).","journal-title":"Lancet Lond. Engl."},{"key":"23757_CR25","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","volume":"386","author":"R Khanna","year":"2015","unstructured":"Khanna, R. et al. Early combined immunosuppression for the management of Crohn\u2019s disease (REACT): A cluster randomised controlled trial. Lancet Lond. Engl. 386, 1825\u20131834 (2015).","journal-title":"Lancet Lond. Engl."},{"key":"23757_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cels.2017.12.013","volume":"6","author":"BD Piening","year":"2018","unstructured":"Piening, B. D. et al. Integrative personal omics profiles during periods of weight gain and loss. Cell Syst. 6, 157-170.e8 (2018).","journal-title":"Cell Syst."},{"key":"23757_CR27","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41586-019-1236-x","volume":"569","author":"W Zhou","year":"2019","unstructured":"Zhou, W. et al. Longitudinal multi-omics of host-microbe dynamics in prediabetes. Nature 569, 663\u2013671 (2019).","journal-title":"Nature"},{"key":"23757_CR28","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.csbj.2021.01.028","volume":"19","author":"RB Ghannam","year":"2021","unstructured":"Ghannam, R. B. & Techtmann, S. M. Machine learning applications in microbial ecology, human microbiome studies, and environmental monitoring. Comput. Struct. Biotechnol. J. 19, 1092\u20131107 (2021).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"23757_CR29","doi-asserted-by":"publisher","first-page":"6923","DOI":"10.3748\/wjg.v26.i44.6923","volume":"26","author":"A Kohli","year":"2020","unstructured":"Kohli, A., Holzwanger, E. A. & Levy, A. N. Emerging use of artificial intelligence in inflammatory bowel disease. World J. Gastroenterol. 26, 6923\u20136928 (2020).","journal-title":"World J. Gastroenterol."},{"key":"23757_CR30","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.chom.2014.02.005","volume":"15","author":"D Gevers","year":"2014","unstructured":"Gevers, D. et al. The treatment-naive microbiome in new-onset Crohn\u2019s disease. Cell Host Microbe 15, 382\u2013392 (2014).","journal-title":"Cell Host Microbe"},{"key":"23757_CR31","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/nrmicro3255","volume":"12","author":"U Hofer","year":"2014","unstructured":"Hofer, U. Microbiome: Bacterial imbalance in Crohn\u2019s disease. Nat. Rev. Microbiol. 12, 312 (2014).","journal-title":"Nat. Rev. Microbiol."},{"key":"23757_CR32","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41591-018-0308-z","volume":"25","author":"B Yilmaz","year":"2019","unstructured":"Yilmaz, B. et al. Microbial network disturbances in relapsing refractory Crohn\u2019s disease. Nat. Med. 25, 323\u2013336 (2019).","journal-title":"Nat. Med."},{"key":"23757_CR33","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.chom.2017.04.010","volume":"21","author":"AN Ananthakrishnan","year":"2017","unstructured":"Ananthakrishnan, A. N. et al. Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases. Cell Host Microbe 21, 603-610.e3 (2017).","journal-title":"Cell Host Microbe"},{"key":"23757_CR34","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1373\/49.6.861","volume":"49","author":"A Carroccio","year":"2003","unstructured":"Carroccio, A. et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: A prospective study in adults and children. Clin. Chem. 49, 861\u2013867 (2003).","journal-title":"Clin. Chem."},{"key":"23757_CR35","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1136\/gut.2005.069476","volume":"55","author":"S Vermeire","year":"2006","unstructured":"Vermeire, S., Van Assche, G. & Rutgeerts, P. Laboratory markers in IBD: Useful, magic, or unnecessary toys?. Gut 55, 426\u2013431 (2006).","journal-title":"Gut"},{"key":"23757_CR36","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/ecco-jcc\/jjv150","volume":"9","author":"F Goutorbe","year":"2015","unstructured":"Goutorbe, F. et al. Endoscopic factors influencing fecal calprotectin value in Crohn\u2019s disease. J. Crohns Colitis 9, 1113\u20131119 (2015).","journal-title":"J. Crohns Colitis"},{"key":"23757_CR37","first-page":"978","volume":"20","author":"S Rajca","year":"2014","unstructured":"Rajca, S. et al. Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn\u2019s disease. Inflamm. Bowel Dis. 20, 978\u2013986 (2014).","journal-title":"Inflamm. Bowel Dis."},{"key":"23757_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101669","volume":"45","author":"S Buffet-Bataillon","year":"2021","unstructured":"Buffet-Bataillon, S., Landreau, C., Siproudhis, L., Cattoir, V. & Bouguen, G. Bacterial gut dysbiosis is associated with Crohn\u2019s disease symptoms but not with elevated fecal calprotectin. Clin. Res. Hepatol. Gastroenterol. 45, 101669 (2021).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"23757_CR39","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fmicb.2020.00065","volume":"11","author":"A Neumann","year":"2020","unstructured":"Neumann, A., Bj\u00f6rck, L. & Frick, I.-M. Finegoldia magna, an anaerobic Gram-positive bacterium of the normal human microbiota, induces inflammation by activating neutrophils. Front. Microbiol. 11, 65 (2020).","journal-title":"Front. Microbiol."},{"key":"23757_CR40","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1053\/j.gastro.2020.09.036","volume":"160","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. Elucidation of Proteus mirabilis as a key bacterium in Crohn\u2019s disease inflammation. Gastroenterology 160, 317-330.e11 (2021).","journal-title":"Gastroenterology"},{"key":"23757_CR41","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1126\/science.1241165","volume":"341","author":"PM Smith","year":"2013","unstructured":"Smith, P. M. et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341, 569\u2013573 (2013).","journal-title":"Science"},{"key":"23757_CR42","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature12721","volume":"504","author":"Y Furusawa","year":"2013","unstructured":"Furusawa, Y. et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504, 446\u2013450 (2013).","journal-title":"Nature"},{"key":"23757_CR43","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.chom.2016.07.001","volume":"20","author":"M Kim","year":"2016","unstructured":"Kim, M., Qie, Y., Park, J. & Kim, C. H. Gut microbial metabolites fuel host antibody responses. Cell Host Microbe 20, 202\u2013214 (2016).","journal-title":"Cell Host Microbe"},{"key":"23757_CR44","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1073\/pnas.1322269111","volume":"111","author":"PV Chang","year":"2014","unstructured":"Chang, P. V., Hao, L., Offermanns, S. & Medzhitov, R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc. Natl. Acad. Sci. USA 111, 2247\u20132252 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"23757_CR45","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/mi.2016.114","volume":"10","author":"W Wu","year":"2017","unstructured":"Wu, W. et al. Microbiota metabolite short-chain fatty acid acetate promotes intestinal IgA response to microbiota which is mediated by GPR43. Mucosal Immunol. 10, 946\u2013956 (2017).","journal-title":"Mucosal Immunol."},{"key":"23757_CR46","doi-asserted-by":"publisher","first-page":"eaao4755","DOI":"10.1126\/scitranslmed.aao4755","volume":"10","author":"NA Scott","year":"2018","unstructured":"Scott, N. A. et al. Antibiotics induce sustained dysregulation of intestinal T cell immunity by perturbing macrophage homeostasis. Sci. Transl. Med. 10, eaao4755 (2018).","journal-title":"Sci. Transl. Med."},{"key":"23757_CR47","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/268462a0","volume":"268","author":"MG Riggs","year":"1977","unstructured":"Riggs, M. G., Whittaker, R. G., Neumann, J. R. & Ingram, V. M. n-Butyrate causes histone modification in HeLa and friend erythroleukaemia cells. Nature 268, 462\u2013464 (1977).","journal-title":"Nature"},{"key":"23757_CR48","doi-asserted-by":"publisher","first-page":"2485S","DOI":"10.1093\/jn\/133.7.2485S","volume":"133","author":"JR Davie","year":"2003","unstructured":"Davie, J. R. Inhibition of histone deacetylase activity by butyrate. J. Nutr. 133, 2485S-2493S (2003).","journal-title":"J. Nutr."},{"key":"23757_CR49","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000335672","volume":"58","author":"GM Matthews","year":"2012","unstructured":"Matthews, G. M., Howarth, G. S. & Butler, R. N. Short-chain fatty acids induce apoptosis in colon cancer cells associated with changes to intracellular redox state and glucose metabolism. Chemotherapy 58, 102\u2013109 (2012).","journal-title":"Chemotherapy"},{"key":"23757_CR50","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/cdd.2010.117","volume":"18","author":"Y Tang","year":"2011","unstructured":"Tang, Y., Chen, Y., Jiang, H. & Nie, D. Short-chain fatty acids induced autophagy serves as an adaptive strategy for retarding mitochondria-mediated apoptotic cell death. Cell Death Differ. 18, 602\u2013618 (2011).","journal-title":"Cell Death Differ."},{"key":"23757_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147218","volume":"11","author":"J Zhang","year":"2016","unstructured":"Zhang, J. et al. Sodium butyrate induces endoplasmic reticulum stress and autophagy in colorectal cells: Implications for apoptosis. PLoS ONE 11, e0147218 (2016).","journal-title":"PLoS ONE"},{"key":"23757_CR52","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1038\/s41564-019-0483-9","volume":"4","author":"S Vieira-Silva","year":"2019","unstructured":"Vieira-Silva, S. et al. Quantitative microbiome profiling disentangles inflammation- and bile duct obstruction-associated microbiota alterations across PSC\/IBD diagnoses. Nat. Microbiol. 4, 1826\u20131831 (2019).","journal-title":"Nat. Microbiol."},{"key":"23757_CR53","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40168-020-0792-5","volume":"8","author":"H Sokol","year":"2020","unstructured":"Sokol, H. et al. Fecal microbiota transplantation to maintain remission in Crohn\u2019s disease: A pilot randomized controlled study. Microbiome 8, 12 (2020).","journal-title":"Microbiome"},{"key":"23757_CR54","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/jcp.25911","volume":"233","author":"M Ganji-Arjenaki","year":"2018","unstructured":"Ganji-Arjenaki, M. & Rafieian-Kopaei, M. Probiotics are a good choice in remission of inflammatory bowel diseases: A meta analysis and systematic review. J. Cell. Physiol. 233, 2091\u20132103 (2018).","journal-title":"J. Cell. Physiol."},{"key":"23757_CR55","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/apt.14203","volume":"46","author":"Y Derwa","year":"2017","unstructured":"Derwa, Y., Gracie, D. J., Hamlin, P. J. & Ford, A. C. Systematic review with meta-analysis: The efficacy of probiotics in inflammatory bowel disease. Aliment. Pharmacol. Ther. 46, 389\u2013400 (2017).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"23757_CR56","doi-asserted-by":"publisher","first-page":"11450","DOI":"10.1038\/s41598-017-11734-8","volume":"7","author":"A Geirnaert","year":"2017","unstructured":"Geirnaert, A. et al. Butyrate-producing bacteria supplemented in vitro to Crohn\u2019s disease patient microbiota increased butyrate production and enhanced intestinal epithelial barrier integrity. Sci. Rep. 7, 11450 (2017).","journal-title":"Sci. Rep."},{"key":"23757_CR57","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1177\/1756283X17732720","volume":"10","author":"PB Allen","year":"2017","unstructured":"Allen, P. B., Gower-Rousseau, C., Danese, S. & Peyrin-Biroulet, L. Preventing disability in inflammatory bowel disease. Ther. Adv. Gastroenterol. 10, 865\u2013876 (2017).","journal-title":"Ther. Adv. Gastroenterol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23757-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23757-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23757-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T21:19:05Z","timestamp":1668892745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23757-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,19]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["23757"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-23757-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,19]]},"assertion":[{"value":"11 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19929"}}